CACNA1F (Cav1.4) (cytoplasmic domain) Antikörper

Antigen: CACNA1F (Cav1.4)

Epitope: cytoplasmic domain

Klonalität: Polyklonal

Wirt: Kaninchen

Applikation: Immunhistochemie (IHC), Western Blot (WB)

Produktnummer: ABIN350142

Produktbeschreibung

Weitere Bezeichnung: CACNA1F (Cav1.4) (cytoplasmic domain)

Swiss-Prot: O60840

Immunogen: A synthetic peptide from a cytoplasmic domain of human CACNA1F (Cav1.4) conjugated to an immunogenic carrier protein was used as the immunogen.

Format: Lyophilized

Beschreibung: Function: Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1F gives rise to L-type calcium currents. Long-lasting (L-type) calcium channels belong to the 'high-voltage activated' (HVA) group. They are blocked by dihydropyridines (DHP), phenylalkylamines, benzothiazepines, and by omega-agatoxin-IIIA (omega-Aga-IIIA). They are however insensitive to omega-conotoxin-GVIA (omega-CTx-GVIA) and omega-agatoxin-IVA (omega-Aga-IVA). Subcellular location: Membrane; Multi-pass membrane protein. Also known as: Voltage-gated calcium channel subunit alpha Cav1.4, Voltage-dependent L-type calcium channel subunit alpha-1F, CACNAF1.

Spezifität: Appears to be specific for CACNA1F.

Anwendungen

Applikationshinweise: IHC, WB. A dilution of 1 : 300 to 1 : 2000 is recommended. The optimal dilution should be determined by the end user. Not tested in other applications.

Reinheit: whole serum

Lagerung: Maintain the lyophilised/reconstituted antibodies frozen at -20°C for long term storage and refrigerated at 2-8°C for a shorter term. When reconstituting, glycerol (1:1) may be added for an additional stability. Avoid freeze and thaw cycles.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Publikationen

Publikationen: Strom, Nyakatura, Apfelstedt-Sylla et al.: "An L-type calcium-channel gene mutated in incomplete X-linked congenital stationary night blindness." in: Nature genetics, Vol. 19, Issue 3, pp. 260-3, 1998 (PubMed).

Wutz, Sauer, Zrenner et al.: "Thirty distinct CACNA1F mutations in 33 families with incomplete type of XLCSNB and Cacna1f expression profiling in mouse retina." in: European journal of human genetics : EJHG, Vol. 10, Issue 8, pp. 449-56, 2002 (PubMed).

Ross, Grafham, Coffey et al.: "The DNA sequence of the human X chromosome." in: Nature, Vol. 434, Issue 7031, pp. 325-37, 2005 (PubMed).

Hemara-Wahanui, Berjukow, Hope et al.: "A CACNA1F mutation identified in an X-linked retinal disorder shifts the voltage dependence of Cav1.4 channel activation." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, Issue 21, pp. 7553-8, 2005 (PubMed).

Jalkanen, Bech-Hansen, Tobias et al.: "A novel CACNA1F gene mutation causes Aland Island eye disease." in: Investigative ophthalmology & visual science, Vol. 48, Issue 6, pp. 2498-502, 2007 (PubMed).